8-K: IO Biotech's Cylembio Shows Promise in Melanoma, Eyes New Phase 3

IO Biotech presented updated clinical data for its Cylembio drug candidate at the Jefferies Global Healthcare Conference, highlighting promising Phase 3 results in advanced melanoma and outlining plans for future trials and regulatory submissions.

Summary

• IO Biotech participated in the Jefferies Global Healthcare Conference on November 18, 2025, presenting an updated corporate investor deck.
• The company's lead product candidate, Cylembio (IO102-IO103), demonstrated clinical improvement in Progression-Free Survival (PFS) in the IOB-013 Phase 3 study for first-line advanced melanoma.
• Median PFS was 19.4 months for Cylembio plus pembrolizumab versus 11.0 months for pembrolizumab alone (HR=0.77, CI 0.58-1.00, p=0.056), narrowly missing the statistical significance threshold of p=0.045.
• PFS improvement was observed across virtually all subgroups and stratification factors, including a significant improvement in PD-L1 negative patients (mPFS 16.6 months vs. 3.0 months, HR: 0.54, nominal p=0.006).
• The Cylembio combination was well-tolerated, showing no significant added systemic toxicity compared to pembrolizumab monotherapy.
• An Overall Survival (OS) trend favoring the Cylembio combination arm was observed, though OS data is not yet mature (HR = 0.79, CI 0.57, 1.10).
• IO Biotech plans to align on a new Phase 3 design (IOB-023) with the FDA and discuss submission of Marketing Authorization Applications (MAAs) based on IOB-013 data with the European Medicines Agency (EMA).
• The company is also developing Cylembio for Non-Small Cell Lung Cancer (NSCLC) and Squamous Cell Carcinoma of the Head and Neck (SCCHN), with encouraging Phase 2 data in both indications.
• The global melanoma drug market is projected to reach $13.2 billion by 2030, growing at a 9% CAGR from $9.4 billion in 2024.
• Cash balance is sufficient through Q1 2026, with approximately $31 million as of Q3 2025.

Sentiment

Score: 7

Explanation: While the primary endpoint for statistical significance was narrowly missed, the clinical improvement in PFS, favorable safety profile, and strong performance in subgroups, combined with promising data in other indications and strategic plans for future trials and regulatory submissions, indicate a positive outlook despite the technical miss.

Positives

• Cylembio demonstrated clinical improvement in PFS in Phase 3 advanced melanoma study (IOB-013), with a median PFS of 19.4 months vs. 11.0 months for pembrolizumab alone.
• The combination showed a favorable safety profile with no significant added systemic toxicity compared to pembrolizumab monotherapy.
• Significant PFS improvement was observed in the hard-to-treat PD-L1 negative subgroup (mPFS 16.6 months vs. 3.0 months, nominal p=0.006).
• An early and widening trend in Overall Survival (OS) favoring Cylembio was noted, though data is not yet mature.
• Encouraging Phase 2 data for Cylembio in NSCLC (ORR 55% unconfirmed/48% confirmed; mPFS 8.1 months vs. benchmark ORR 39%, mPFS 6.5 months) and SCCHN (ORR 44.4%; mPFS 6.6 months vs. benchmark ORR 23%, mPFS 3.4 months).
• The company is pursuing a new adaptive Phase 3 trial design (IOB-023) for advanced melanoma, potentially incorporating a triple combination therapy.
• The T-win platform has broad potential, with preclinical programs in Arginase 1 and TGFb, and potential applications beyond oncology.
• Cylembio is an "off-the-shelf" treatment, offering rapid administration and convenient storage.

Negatives

• The primary endpoint of statistical significance for PFS in the IOB-013 Phase 3 study (p=0.056) was narrowly missed against a threshold of p=0.045.

Risks

• Forward-looking statements are subject to risks and uncertainties, including those related to the execution of the business plan, success and timing of clinical trials, and regulatory submissions.
• Actual results and developments could be materially different from forward-looking statements due to inaccurate assumptions or known/unknown risks and uncertainties.
• Cylembio is an investigational drug candidate not yet approved by the US FDA or other regulatory authorities.
• Comparisons across clinical trials should be interpreted with caution due to differences in study design, patient populations, endpoints, and other factors.
• Initiation of the proposed IOB-023 adaptive Phase 3 clinical trial is subject to raising additional capital.

Future Outlook

IO Biotech plans to align with the FDA on a new adaptive Phase 3 trial design (IOB-023) for first-line advanced melanoma, potentially involving a triple combination therapy. They also intend to discuss submission of Marketing Authorization Applications (MAAs) with the EMA based on the IOB-013 data. The company expects initial data from its neoadjuvant/adjuvant Phase 2 study in 2H 2025, with presentation in 2026, and plans an IND submission for its IO112 program in 2026. The T-win platform is envisioned to expand into other cancer indications and potentially infectious, inflammatory, and auto-immune diseases.

Management Comments

• Cylembio is an ideal combination partner potential for clinical improvement across a number of combination agents without additional systemic toxicity.
• Cylembio has potential to address a high unmet medical need by improving clinical effect without adding systemic toxicity.
• Cylembio profile has potential to fulfill significant unmet needs and drive market leadership.
• IO102-IO103 has demonstrated improvement in PFS, trend towards long and durable response including in hard-to-treat subgroups, with favorable safety across a number of combination agents in clinical studies.
• The proposed adaptive Phase 3 trial aims to give IOBT the potential to jump ahead with the goal of becoming the first triple combination therapy.
• IO Biotechs T-win cancer vaccine platform is designed to provide a new therapeutic strategy with the potential to improve outcomes for patients with cancer by killing tumor cells and turning the tumor micro-environment hostile to cancer cells.

Industry Context

The filing highlights a significant unmet medical need in advanced melanoma, where approximately 50% of patients progress within one year of treatment, necessitating novel combinations to improve outcomes. The global melanoma drug market is substantial and growing, indicating a strong commercial opportunity for effective new therapies. IO Biotech positions Cylembio as an "ideal combination partner" that can deliver clinical activity without significant tolerability issues, aiming to lead the development of triplet combination therapies, which could represent the future standard of care. The T-win platform's potential expansion beyond oncology into infectious, inflammatory, and auto-immune diseases suggests a broader strategic vision within the biotech industry.

Comparison to Industry Standards

• Cylembio plus pembrolizumab achieved a median PFS of 19.4 months in 1L advanced melanoma, compared to 11.0 months for pembrolizumab alone.
• The observed OS trend (HR=0.79) is stated to be "in line with 12 month OS data reported from other IO combinations."
• In 1L recurrent/metastatic SCCHN, Cylembio showed an ORR of 44.4% and mPFS of 6.6 months, compared to a benchmark ORR of 23% and mPFS of 3.4 months for pembrolizumab alone (KEYNOTE-048, PD-L1 CPS ≥20%).
• In 1L metastatic NSCLC, Cylembio demonstrated an ORR of 55% (unconfirmed)/48% (confirmed) and mPFS of 8.1 months, compared to a benchmark ORR of 39% and mPFS of 6.5 months for pembrolizumab alone (KEYNOTE-042, PD-L1 TPS ≥50%).
• The company aims for Cylembio to become the "first triple combination therapy" in advanced melanoma, positioning it ahead of current standard-of-care (SoC) anti-PD1 monotherapy or anti-PD1 combinations with anti-CTLA4 or anti-LAG3 agents.

Stakeholder Impact

• Shareholders: Potential for increased value if Cylembio gains regulatory approval and market share, but also risk from the narrow miss on statistical significance and need for further capital.
• Patients: Potential for a new, effective, and well-tolerated treatment option for advanced melanoma and other solid tumors, especially for those who progress on current therapies or are PD-L1 negative.
• Healthcare Providers: Cylembio's "off-the-shelf" nature and subcutaneous administration could offer convenience and faster access to treatment.
• Employees: Continued employment and potential growth opportunities as the company advances its pipeline.
• Creditors (EIB): Repayment of loan facilities is dependent on the company's future success and financial health.

Next Steps

• Align on new Phase 3 design (IOB-023) with the FDA.
• Discuss submission of Marketing Authorization Applications (MAAs) based on IOB-013 data with the EMA.
• Initiate new Phase 3 study (IOB-023) (subject to capital raise).
• Present initial data from neoadjuvant/adjuvant Ph2 in 2026 (data available 2H25).
• Continue readiness for IND submission for IO112.
• IND submission for IO112 planned in 2026.
• Further develop IO170 (pre-clinical).
• Expand the T-win platform into other types of diseases (infectious, inflammatory, auto-immune).

Key Dates

Recommendation

While the Phase 3 trial for Cylembio in advanced melanoma narrowly missed its primary statistical significance endpoint, the observed clinical improvement in PFS, particularly in the PD-L1 negative subgroup, and the favorable safety profile are compelling. The company's strategic plan to engage with the FDA for a new adaptive Phase 3 design and with the EMA for MAA submissions, coupled with promising Phase 2 data in NSCLC and SCCHN, suggests continued potential. However, the technical miss on the primary endpoint introduces a degree of uncertainty, and the need for additional capital for the proposed IOB-023 trial is a factor. Investors should hold to monitor the outcomes of regulatory discussions, the design and initiation of the next Phase 3 trial, and further clinical data readouts, especially the maturing OS data. The current cash runway through Q1 2026 also warrants attention regarding future financing.

Keywords

IO Biotech, Cylembio, IOBT, Melanoma, Advanced Melanoma, Oncology, Cancer Vaccine, Immunotherapy, Pembrolizumab, Keytruda, PD-1 inhibitor, IDO1, PD-L1, Clinical Trials, Phase 3, PFS, Overall Survival, FDA, EMA, Biotechnology, Pharmaceuticals, NSCLC, SCCHN, T-win platform, Jefferies Global Healthcare Conference